Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient

Journal of Bone and Mineral Research

Volumn 26, Issue 10, 2011, Pages 2439-2451

  Battaglia, Séverine ^a,b   Dumoucel, Sophie ^a,b,c   Chesneau, Julie ^a,b   Heymann, Marie Françoise ^a,b,d   Picarda, Gaëlle ^a,b   Gouin, François ^a,b,d   Corradini, Nadège ^a,b,c   Heymann, Dominique ^a,b   Redini, Françoise ^a,b  

^a Universite de Nantes   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Hopital Mere Enfant CHU de Nantes   (France)

^d HÔTEL DIEU   (France)

Author keywords

bone growth; bone resorption; Ewing sarcoma; osteosarcoma; zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BONE GROWTH; BONE RADIOGRAPHY; BONE REMODELING; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DIAPHYSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; ENCHONDRAL OSSIFICATION; EWING SARCOMA; FEMALE; GROWTH DISORDER; GROWTH PLATE; HEMATOPOIESIS; HISTOPATHOLOGY; HUMAN; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOSARCOMA; SCHOOL CHILD; SPLEEN; TIBIA;

ANIMALS; BONE DEVELOPMENT; BONE NEOPLASMS; CHILD; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; OSTEOSARCOMA;

EID: 80053198681     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.453     Document Type: Article

References (52)

1. Marina N, Gebhardt M, Teot L, Gorlick R,. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9: 422-441. (Pubitemid 39014554)
2. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors: a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994; 331: 294-299. (Pubitemid 24236016)
3. Heymann D, Ory B, Blanchard F, Heymann M, Coipeau P, Charrier C, Couillaud S, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005; 37: 74-86. (Pubitemid 40848420)
4. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, et al. Zoledronic acid as new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res. 2010; 70: 7610-7619.
5. Dass CR, Choong PFM,. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther. 2007; 6: 3263-3270.
6. Meyers PA, Healey JH, Chou AJ, Wexler LH, Merola PR, Morris CD, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2010; DOI: 10.1002/cncr.25744.
7. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000; 88: 2961-2978. (Pubitemid 30413179)
8. Rodan GA, Fleisch HA,. Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 87: 2692-2696. (Pubitemid 26197084)
9. Russell RG,. Bisphosphonates: from bench to bedside. Ann NY Acad Sci. 2006; 1068: 367-401. (Pubitemid 43824169)
10. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991; 88: 2095-2105.
11. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995; 10: 1478-1487.
12. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ,. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100: 1475-1480. (Pubitemid 27425772)
13. Munns CF, Rauch F, Travers R, Glorieux FH,. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res. 2005; 20: 1235-1243. (Pubitemid 40863813)
14. Fleisch H,. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs. 1991; 42: 919-944. (Pubitemid 21920790)
15. Bone HG,. Ten years' experience with alendronate for osteoporosis in postmenoposal women. N Engl J Med. 2004; 350: 1189-1199. (Pubitemid 38339363)
16. Heymann D, Ory B, Gouin F, Green JR, Rédini F,. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med. 2004; 10: 337-343. (Pubitemid 38881523)
17. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A,. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res. 2009; 15: 3451-3461.
18. Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 2009; 44: 908-916.
19. Giuliani N, Pedrazzoni M, Passeri G, Girasole G,. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol. 1998; 27: 38-41. (Pubitemid 28116468)
20. Tenta R, Sourla A, Lembessis P, Koutsilieris M,. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Anticancer Res. 2006; 26: 283-291. (Pubitemid 43206088)
21. Muraro M, Mereuta OM, Saglio F, Carraro F, Berger M, Madon E, et al. Interactions between osteosarcoma cell lines and dendritic cells immune function: an in vitro study. Cell Immunol. 2008; 253: 71-80.
22. Chauvin C, Philippeau J, Hémont C, Hubert F, Wittrant Y, Lamoureux F, et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res. 2008; 68: 9433-9440.
23. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F,. The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs. 2003; 14: 767-771. (Pubitemid 37357703)
24. Zhou Z, Guan H, Duan X, Kleinerman ES,. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 2005; 104: 1713-1720. (Pubitemid 41437436)
25. Benassi MS, Chiechi A, Ponticelli F, Pazzaglia L, Gamberi G, Zanella L, et al. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett. 2007; 250: 194-205. (Pubitemid 46529443)
26. Murayama T, Kawasoe Y, Yamashita Y, Ueno Y, Minami S, Yokouchi M, et al. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res. 2008; 42: 2147-2154.
27. Kubo T, Shimose S, Matsuo T, Sakai A, Ochi M,. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen-activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol. 2008; 62: 111-116. (Pubitemid 351537851)
28. Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, et al. Combined effects of a third-generation bisphosphonate, zoledronic acid, with other anticancer agents against murine osteosarcoma. Br J Cancer. 2007; 96: 255-261. (Pubitemid 46160630)
29. Brown JJ, Zacharin MR,. Safety and efficacy of intravenous zoledronic acid in pediatric osteoporosis. J Pediatr Endocrinol Metab. 2009; 22: 55-63.
30. Rauch F, Cornibert S, Cheung M, Glorieux FH,. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfect. Bone. 2007; 40: 821-827. (Pubitemid 46386546)
31. Price AP, Abramson SJ, Hwang S, Chou A, Bartolotta R, Meyers P, et al. Skeletal imaging effects of pamidronate therapy in osteosarcoma patients. Pediatr Radiol. 2010; 10;1007/s00247-010-1883-4.
32. Smith EJ, Little DG, Briody JN, McEvoy A, Smith NC, Eisman JA, et al. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits. J Bone Miner Res. 2005; 20: 1731-1741. (Pubitemid 41361874)
33. Rao SH, Evans KD, Oberbauer AM, Martin RB,. Bisphosphonate treatment in the OIM mouse model alters bone modeling during growth. J Biomech. 2008; 41: 3371-3376.
34. Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfect. Calcif Tissue Int. 2001; 69: 94-101. (Pubitemid 32762911)
35. Miyamoto N, Higuchi Y, Mori K, Ito M, Tsurudome M, Nishio M, et al. Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol. 2002; 2: 25-38. (Pubitemid 33086801)
36. Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Rédini F,. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Exp Rev Anticancer Res. 2007; 7: 169-181. (Pubitemid 46277282)
37. Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007; 67: 7308-7318. (Pubitemid 47206560)
38. Ashton JA, Farese JP, Milner RJ, Lee-Ambrose LM, van Gilder JM, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res. 2005; 66: 885-891. (Pubitemid 40812684)
39. Cheng YY, Huang L, Lee KM, Li K, Kumta SM,. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer. 2004; 42: 410-415. (Pubitemid 38524469)
40. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F,. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 2005; 104: 2522-2529. (Pubitemid 41691577)
41. Zeitlin L, Rauch F, Plotkin H, Glorieux FH,. Height and weight development during four years of therapy with cyclical intraveinous pamidronate in children and adolescents with osteogenesis imperfect type I, III, and IV. Pediatrics. 2003; 111: 1030-1036. (Pubitemid 36542617)
42. Hasegawa K, Inoue M, Seino Y, Morishima T, Tanaka H,. Growth of infants with osteogenesis imperfect treated with bisphosphonate. Pediatr Int. 2009; 51: 54-58.
43. Rauch F, Travers R, Munns C, Glorieux FH,. Sclerotic metaphyseal lines in a child treated with pamidronate. J Bone Miner Res. 2004; 19: 1191-1193.
44. Pataki A, Müller K, Green JR, Ma YF, Li QN, Jee WSS,. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during and after treatment. Anat Rec. 1997; 249: 458-468. (Pubitemid 27521594)
45. Allen MR,. Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment. Exp Opin Drug Metab Toxicol. 2008; 4: 1371-1378.
46. Pozzi S, Valet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009; 15: 5829-5839.
47. Munns CF, Mansoor HR, Hong J, Briody J, Högler W, McQuade M, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007; 41: 366-370. (Pubitemid 47199149)
48. Castillo H, Samson-Fang L,. American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009; 51: 17-29.
49. Marini JC,. Bone: use of bisphosphonates in children-proceed with caution. Nat Rev Endocrinol. 2009; 5: 241-243.
50. Evans KD, Lau ST, Oberbauer AM, Martin RB,. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfect. Bone. 2003; 32: 268-274. (Pubitemid 36349530)
51. Van Offel JF, Schuerwegh AJ, Bridts CH, Stevens WJ, De Clerck LS,. Effect of bisphosphonates on viability, proliferation and dexamethasone-induced apoptosis of articular chondrosytes. Ann Rheum Dis. 2002; 61: 925-928.
52. Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397: 315-323.